Algorithme Pharma, an Altasciences company, has completed the validation of its expanded bioanalytical offering, Ligand Binding Bioanalysis.

The new service allows the company to further enhance the support of Phase I/first-in-human and late-phase clinical trials conducted locally or globally, providing key information for sponsors as they look to make critical decisions in a timely fashion.

The Ligand Binding Bioanalysis team, headed by scientific executive Dr. Robert Massé, offers extensive experience in the development and validation of quantitative immunoassays for the measurement of biological compounds. The scientists can develop methods from commercially available kits or customized de novo ELISA in different formats (e.g. competitive direct, indirect and sandwich) for determining therapeutic proteins, monoclonal antibodies, peptides or biomarkers in various biological matrices. For oligonucleotides, ELISA methods coupled with hybridization techniques are applied for quantitation.

“As sponsors look to answer many more questions during early stage clinical development, the studies we are conducting are increasingly complex. This additional expertise better allows us to provide the key information required for early drug development decisions — which is critical in getting drugs to market rapidly,” said Chris Perkin, president and chief executive officer of Altasciences.